ADA and liver cancer: Monoclonal antibodies require long‐term use, which not only lacks accurate tumor targeting but also produces adverse reactions, such as anti‐drug antibodies (ADA).[38] To inhibit the effect of GDF15 more efficiently, we used gene editing to knock out GDF15 in tumor cells at the gene level, which has better targeting, specificity, and long‐term performance, and provides a novel method for GDF15‐targeted liver cancer immunotherapy.[21]